Circulating microRNA: The Potential Novel Diagnostic Biomarkers to Predict Drug Resistance in Temporal Lobe Epilepsy, a Pilot Study

International Journal of Molecular Sciences, Vol. 22 (2021)

Mots clés
Authors
  • Selene De Benedittis
  • Department of Medical and Surgical Sciences, Institute of Neurology, University “Magna Graecia”, Germaneto, 88100 Catanzaro, Italy
  • Francesco Fortunato
  • Department of Medical and Surgical Sciences, Institute of Neurology, University “Magna Graecia”, Germaneto, 88100 Catanzaro, Italy
  • Claudia Cava
  • Institute of Molecular Bioimaging and Physiology (IBFM), National Research Council (CNR), Via F.Cervi 93, 20090 Segrate-Milan, Italy
  • Francesca Gallivanone
  • Institute of Molecular Bioimaging and Physiology (IBFM), National Research Council (CNR), Via F.Cervi 93, 20090 Segrate-Milan, Italy
  • Enrico Iaccino
  • Department of Experimental and Clinical Medicine, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy
  • Maria Eugenia Caligiuri
  • Neuroscience Research Center, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy
  • Isabella Castiglioni
  • Institute of Molecular Bioimaging and Physiology (IBFM), National Research Council (CNR), Via F.Cervi 93, 20090 Segrate-Milan, Italy
  • Gloria Bertoli
  • Institute of Molecular Bioimaging and Physiology (IBFM), National Research Council (CNR), Via F.Cervi 93, 20090 Segrate-Milan, Italy
  • Ida Manna
  • Institute of Molecular Bioimaging and Physiology (IBFM), National Research Council (CNR), Section of Germaneto, 88100 Catanzaro, Italy
  • Angelo Labate
  • Department of Medical and Surgical Sciences, Institute of Neurology, University “Magna Graecia”, Germaneto, 88100 Catanzaro, Italy
  • Antonio Gambardella
  • Department of Medical and Surgical Sciences, Institute of Neurology, University “Magna Graecia”, Germaneto, 88100 Catanzaro, Italy

Résumé

MicroRNAs (miRNAs) are small noncoding RNAs that have emerged as new potential epigenetic biomarkers. Here, we evaluate the efficacy of six circulating miRNA previously described in the literature as biomarkers for the diagnosis of temporal lobe epilepsy (TLE) and/or as predictive biomarkers to antiepileptic drug response. We measured the differences in serum miRNA levels by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) assays in a cohort of 27 patients (14 women and 13 men; mean ± SD age: 43.65 ± 17.07) with TLE compared to 20 healthy controls (HC) matched for sex, age and ethnicity (11 women and 9 men; mean ± SD age: 47.5 ± 9.1). Additionally, patients were classified according to whether they had drug-responsive (n = 17) or drug-resistant (n = 10) TLE. We have investigated any correlations between miRNAs and several electroclinical parameters. Three miRNAs (miR-142, miR-146a, miR-223) were significantly upregulated in patients (expressed as average expression ± SD). In detail, miR-142 expression was 0.40 ± 0.29 versus 0.16 ± 0.10 in TLE patients compared to HC (t-test, p t-test, p t-test, p < 0.001). Moreover, results obtained from a logistic regression model showed the good performance of miR-142 and miR-223 in distinguishing drug-sensitive vs. drug-resistant TLE. The results of this pilot study give evidence that miRNAs are suitable targets in TLE and offer the rationale for further confirmation studies in larger epilepsy cohorts.

Read more: fulltext (text/html)